Q1 2023 Results

Company overview Innovation: Pipeline overview Cardiovascular Financial review Conclusions Financial performance Immunology Cosentyx® - IL-17A inhibitor Appendix Innovation: Clinical trials Neuroscience Oncology Cosentyx® - IL-17A inhibitor NCT04181762 SELUNE (CAIN457Q12301) Indication Lupus Nephritis Phase Phase 3 NCT04930094 GCAPTAIN (CAIN457R12301) Indication Phase Giant cell arteritis Phase 3 Patients 460 Patients 348 Primary Proportion of subjects achieving protocol-defined CRR Outcome Primary Outcome Number of participants with sustained remission Measures Measures Arms Secukinumab 300 mg s.c. Intervention Placebo s.c. Target Patients Patients with active lupus nephritis (ISN/RPS Class III or IV, with or without co-existing class V features) Readout Milestone(s) 2025 Publication TBD Target Patients Experimental: Secukinumab 300 mg Placebo Comparator: Placebo Patients with Giant Cell Arteritis (GCA) Primary 2025 Final 2026 Readout Milestone(s) Publication TBD Arms Intervention 54 Investor Relations | Q1 2023 Results References Abbreviations Other NOVARTIS | Reimagining Medicine

View entire presentation